The award recognizes a progression of discoveries that transformed neuroscience from observational science to one capable of causal perturbation. In the early 2000s, Hegemann and Nagel discovered channelrhodopsin, a protein found on the surface of *Chlamydomonas*, a single-celled alga. They observed that when this protein is illuminated by blue light, a channel opens, allowing charged ions to flow into the cell and create an electrical impulse. Crucially, they found that regardless of the cell type into which the protein was introduced, those cells became light-sensitive.
Karl Deisseroth, a professor of bioengineering and psychiatry at Stanford University, transformed this algal protein into a functional tool for neuroscience. In 2005, he published a breakthrough in which he introduced the gene for channelrhodopsin into rat nerve cells, successfully triggering nerve signals with blue light. Two years later, he demonstrated that this light-controlled switch worked in the brains of living mice. This method, now known as optogenetics, provides a way to precisely control neural activity, moving beyond the limitations of earlier techniques that could only observe brain activity without establishing causal relationships.
Per Svenningsson, Chair of the Nobel Committee for Physiology or Medicine, stated that optogenetics provides opportunities for mapping the brain in ways previously only conceivable in theory. By allowing researchers to manipulate specific neurons millisecond by millisecond, the technique has enabled the identification of neural circuits governing specific memories, feelings, and behaviors. This has laid the foundation for a new era in neuroscience, shifting the field’s understanding from a “sketch map” of unknowns to a precise understanding of how the brain governs bodily functions and cognition.
The practical implications of this work are already evident in clinical research. Scientists are currently using optogenetic methods in attempts to restore sight in individuals with visual impairment. Furthermore, the precise control afforded by the technique suggests potential therapeutic applications for neurological and psychiatric disorders, including epilepsy and mental health conditions, though these remain areas of active investigation rather than established treatments.
“Optogenetics is an engine for discovery,” Deisseroth said. “It’s for probing complex systems at the fundamental level of cells. We want to understand how the brain works as an intact system to carry out complex cognitions, behaviors and perceptions while being anchored and grounded in the elemental cellular level.”
Deisseroth, who holds the D. H. Chen Professorship at Stanford, noted that the award captures the full journey of discovery, spanning from early algal explorations to advanced neuroscience experiments. He emphasized that the core principle of optogenetics is “precise causal perturbation,” which allows researchers to search for ways to understand healthy brain function and identify how it goes wrong.
The discovery of channelrhodopsin and its application in mammals represent a significant shift in how scientists approach the complexity of the human brain. While earlier methods could visualize brain structure and measure function, optogenetics adds the capacity for control. This technological advance has allowed neuroscientists to unravel complexities that were previously beyond reach, providing a clearer path toward understanding and potentially treating conditions rooted in neural dysfunction.
Stanford University President Jonathan Levin described Deisseroth as a “defining figure in modern neuroscience,” noting that his work has unlocked new understanding of the brain and created new possibilities for treating disorders. The recognition highlights the importance of interdisciplinary approaches, bridging bioengineering and psychiatry to solve fundamental biological questions.
As the field continues to evolve, researchers aim to further utilize optogenetics to understand the intact brain system, moving from cellular-level mechanisms to complex cognitive and behavioral outcomes. The next milestones in this field will likely involve expanding the range of light-gated channels and refining clinical applications for neurological and psychiatric conditions.
